Skip to content
Screener
Niagen Bioscience logo

Niagen Bioscience

NAGE

Niagen Bioscience is a global bioscience company focused on healthy aging through the research and commercialization of nicotinamide adenine dinucleotide (NAD+) precursors.

Market cap
$261.12M-66.5%
Revenue$130.4M+20.8%
Net income$18.6M+32.1%
EPS (diluted)$0.21+23.5%
Trailing twelve months · change vs. prior year

Earnings

Q2 2026 report

August 4, 2026
Revenue$29.8MMiss by $747.3KEPS$0.01Beat by $0.00

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$34.4M
EPS estimate$0.01

Financials

Q1 2026

Income statement

See full
Revenue$31.5M+3.3%
Gross profit$20.0M+3.3%
Operating income$1.6M-67.0%
Net income$6.3M+24.8%
EPS (diluted)$0.07+16.7%

Balance sheet

See full
Cash & equivalents$66.5M+19.7%
Total debt$2.6M-26.9%
Total equity$82.3M+48.8%
Total assets$114.3M+40.6%

Cash flow

See full
Operating cash flow-$1.2M-115%

Valuation & ratios

Valuation

See full
Market cap$261.12M-66.5%
Enterprise value$197.14M-72.7%
P/E14×-29.9×
P/S2×-4.7×

Profitability

See full
Gross margin64.3%+1.8pp
Operating margin10%-2.2pp
Net margin14.3%+1.2pp

Returns & leverage

See full
Return on equity27.1%-6.4pp
Debt / equity0×0.0×
Current ratio4.6×+0.9×

Segments

By segment

See full
Consumer Products segment$22.4M+4.2%
Ingredients segment$8.6M+4.8%
Analytical Reference Standards and Services segment$423.0K-47.8%
Corporate and other$74.0K—

Competitors

By market cap

Abbott logo
Abbott$197.44B-13.7%
Neurogene logo
Neurogene$768.6M+173%
NAG
Niagen Bioscience$261.1M-66.5%
Nature's Sunshine Products logo
Nature's Sunshine Products$251.4M-15.5%
LifeVantage Corporation logo
LifeVantage Corporation$83.4M-50.6%
eXoZymes, Inc. logo
eXoZymes, Inc.$69.8M-14.2%
Biote Corp. logo
Biote Corp.$44.5M-58.3%
Jupiter Neurosciences, Inc. logo
Jupiter Neurosciences, Inc.$6.7M-87.2%

By revenue growth

NAG
Niagen Bioscience+20.8%
Abbott logo
Abbott+8.1%
Nature's Sunshine Products logo
Nature's Sunshine Products+6.8%
Biote Corp. logo
Biote Corp.-7.8%
LifeVantage Corporation logo
LifeVantage Corporation-20.1%

By net margin

NAG
Niagen Bioscience14.29%+1.2pp
Abbott logo
Abbott11.65%-20.8pp
Nature's Sunshine Products logo
Nature's Sunshine Products3.68%+0.5pp
Biote Corp. logo
Biote Corp.3.19%-12.5pp
LifeVantage Corporation logo
LifeVantage Corporation2.78%-1.5pp
eXoZymes, Inc. logo
eXoZymes, Inc.-2,909.12%—

Profile

Niagen Bioscience is a global bioscience company focused on healthy aging through the research and commercialization of nicotinamide adenine dinucleotide (NAD+) precursors. The company leverages a proprietary form of nicotinamide riboside (Niagen) to develop cellular health products that address the natural decline of NAD+ levels in the human body. Its value proposition is built on a robust portfolio of owned and licensed patents and extensive clinical research collaborations with leading global academic institutions.

Competitive position

Niagen Bioscience is a world leader in the NAD+ space, distinguished by its extensive patent portfolio and the ChromaDex External Research Program (CERP).

GeographiesUnited States, Canada, Hong Kong, Macau, European Union, Australia
Customer segmentsRetail consumers, Pharmaceutical manufacturers, Healthcare providers
Business modelB2C e-commerce, B2B ingredient supply, Research and Development, Licensing
SuppliersRaw material chemical suppliers, Contract manufacturers, Academic research institutions, Patent licensors
CustomersIndividual consumers, Amazon, A.S. Watson Group, iHerb, 503B compounding facilities
CountryUnited States of America
Listed2008
CEORobert N. Fried
SectorHealthcare
IndustryBiotechnology
Websiteniagenbioscience.com
FilingsSEC EDGAR

FAQ

What is Niagen Bioscience's market cap?
Niagen Bioscience (NAGE) has a market capitalization of $261.1M and trades on NASDAQ.
What is Niagen Bioscience's revenue and profitability?
Niagen Bioscience generated $130.4M in trailing twelve-month revenue with net income of $18.6M, representing a net margin of 14.3%. Gross margin stands at 64.3%. These figures are based on the Q1 2026 filing.
Who are Niagen Bioscience's competitors?
Niagen Bioscience's key competitors include eXoZymes Inc. Common Stock, Lifevantage Corporation Common Stock (Delaware), Jupiter Neurosciences, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Niagen Bioscience partner with?
Niagen Bioscience's notable partners include A.S. Watson Group, Amazon, iHerb, and others.
What subsidiaries does Niagen Bioscience have?
Niagen Bioscience's subsidiaries include ChromaDex, Inc..
Where is Niagen Bioscience headquartered?
Niagen Bioscience is headquartered in United States of America. It has been publicly traded since 2008.